Assigned ID Abstract Title Presenting Author First Name Presenting Author Last Name Accepted Presentation Preference Category Sub-category LBA-001 Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial Talia Golan Oral Presentation Clinical Pancreatic Cancer Metastatic Disease LBA-002 Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study Josep Tabernero Oral Presentation Clinical Gastric Cancer Metastatic Disease LBA-003 A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study) Yoon-Koo Kang Oral Presentation Clinical Gastric Cancer Metastatic Disease LBA-004 Phase 2 study results of murlentamab, a monoclonal antibody targeting the Anti-Mullerian-Hormone-Receptor II (AMHRII), acting through Tumor-Associated Macrophage engagement in advanced/metastatic colorectal cancers Eric Van Cutsem Oral Presentation Clinical Colon Cancer Metastatic Disease LBA-006 BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer Josep Tabernero Oral Presentation Clinical Colon Cancer Clinical LBA-007 Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable mCRC Chiara Cremolini Oral Presentation Clinical Colon Cancer Metastatic Disease O-001 An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes Michele Reni Oral Presentation Clinical Pancreatic Cancer Clinical O-002 Ibrutinib in combination with nab-paclitaxel and gemcitabine as first- line Treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study Margaret Tempero Oral Presentation Clinical Pancreatic Cancer Clinical O-003 Exploratory analysis based on tumor location of REACHIN, a randomized, double-blinded, placebo-controlled phase II trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for advanced/metastatic biliary tract tumors Anne DEMOLS Oral Presentation Clinical Other Clinical O-004 Applied precision cancer medicine in advanced biliary tract cancer Hossein Taghizadeh Oral Presentation Clinical Other Clinical O-005 Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’ trial James Harding Oral Presentation Clinical Other Clinical O-006 Genomic Profiling of Diffuse Gastric Carcinoma (DGC) Jeeyun Lee Oral Presentation Basic Gastric Cancer Biomarkers O-007 ZEBRA: An ACCRU/IRCI Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small Bowel Adenocarcinoma (SBA) Katrina Pedersen Oral Presentation Clinical Other Clinical O-008 Proof of Concept of the Abscopal Effect in MSS GI Cancers: A Phase 2 study of Ipilimumab and Nivolumab with radiation in metastatic pancreatic and colorectal adenocarcinoma Aparna Parikh Oral Presentation Clinical Other Trials in Progress
Transcript
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
LBA-001 Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial
Talia Golan Oral Presentation Clinical Pancreatic Cancer Metastatic Disease
LBA-002 Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study
Josep Tabernero Oral Presentation Clinical Gastric Cancer Metastatic Disease
LBA-003 A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study)
Yoon-Koo Kang Oral Presentation Clinical Gastric Cancer Metastatic Disease
LBA-004 Phase 2 study results of murlentamab, a monoclonal antibody targeting the Anti-Mullerian-Hormone-Receptor II (AMHRII), acting through Tumor-Associated Macrophage engagement in advanced/metastatic colorectal cancers
Eric Van Cutsem Oral Presentation Clinical Colon Cancer Metastatic Disease
LBA-006 BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer
Josep Tabernero Oral Presentation Clinical Colon Cancer Clinical
LBA-007 Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable mCRC
Chiara Cremolini Oral Presentation Clinical Colon Cancer Metastatic Disease
O-001 An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes
Michele Reni Oral Presentation Clinical Pancreatic Cancer Clinical
O-002 Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line Treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study
Margaret Tempero Oral Presentation Clinical Pancreatic Cancer Clinical
O-003 Exploratory analysis based on tumor location of REACHIN, a randomized, double-blinded, placebo-controlled phase II trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for advanced/metastatic biliary tract tumors
Anne DEMOLS Oral Presentation Clinical Other Clinical
O-004 Applied precision cancer medicine in advanced biliary tract cancer Hossein Taghizadeh Oral Presentation Clinical Other Clinical O-005 Treating HER2-mutant advanced biliary tract cancer with neratinib:
benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’ trial
James Harding Oral Presentation Clinical Other Clinical
O-006 Genomic Profiling of Diffuse Gastric Carcinoma (DGC) Jeeyun Lee Oral Presentation Basic Gastric Cancer Biomarkers O-007 ZEBRA: An ACCRU/IRCI Multicenter Phase II Study of
Pembrolizumab in Patients with Advanced Small Bowel Adenocarcinoma (SBA)
Katrina Pedersen Oral Presentation Clinical Other Clinical
O-008 Proof of Concept of the Abscopal Effect in MSS GI Cancers: A Phase 2 study of Ipilimumab and Nivolumab with radiation in metastatic pancreatic and colorectal adenocarcinoma
Aparna Parikh Oral Presentation Clinical Other Trials in Progress
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
O-009 Landscape of FMS-like tyrosine kinase 3 (FLT3) and associated molecular alterations in 44,766 gastrointestinal (GI) cancers
Mohamed Salem Oral Presentation Basic Colon Cancer Biomarkers
O-010 VOLTAGE: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer
Takayuki Yoshino Oral Presentation Clinical Rectal Cancer Clinical
O-011 Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12
Ralf-Dieter Hofheinz Oral Presentation Clinical Rectal Cancer Clinical
O-012 The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer
Jean-Philippe Metges Oral Presentation Clinical Esophageal Cancer Clinical
O-013 Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies
Gemma Zucchelli Oral Presentation Clinical Colon Cancer Metastatic Disease
O-014 Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial.
Per Pfeiffer Oral Presentation Clinical Colon Cancer Metastatic Disease
O-015 Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results.
Per Pfeiffer Oral Presentation Clinical Colon Cancer Metastatic Disease
O-016 Serial assessment of cell-free circulating tumor DNA (ctDNA) to assess treatment effect and minimal residual disease during neoadjuvant and adjuvant therapy in colorectal cancer
Aparna Parikh Oral Presentation Clinical Colon Cancer Biomarkers
O-017 SUNRISE-DI study: decision impact of the 12-gene recurrence score (12-RS) assay on adjuvant chemotherapy recommendation for stage II and IIIA/B colon cancer
Jun Watanabe Oral Presentation Clinical Colon Cancer Clinical
O-018 Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study
Alwers Elizabeth Oral Presentation Clinical Colon Cancer Clinical
O-019 Comprehensive Genomic Profiling (CGP) Defines the Genomic Landscape of Colorectal Cancer (CRC) in Individuals of African Ancestry
Parvathi Myer Oral Presentation Basic Colon Cancer Biomarkers
O-020 Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy
Karen Gambaro Oral Presentation Basic Colon Cancer Metastatic Disease
O-021 Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)
Tim Meyer Oral Presentation Clinical Hepatocellular Clinical
O-022 Outcomes based on Albumin Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
O-023 Significant differences in outcome between Immunoscore categories in stage I colon cancer patients
Jérôme Galon Oral Presentation Basic Colon Cancer Biomarkers
O-024 Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001)
Salvatore Siena Oral Presentation Clinical Other Clinical
O-025 A randomized, multicenter, phase II trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients
Filippo Pietrantonio Oral Presentation Clinical Colon Cancer Clinical
O-026 Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC)
Guillem Argiles Oral Presentation Basic Colon Cancer Biomarkers
O-027 Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240
Richard Finn Oral Presentation Clinical Hepatocellular Clinical
SO-001 Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer.
Shigenori Kadowaki Poster Discussion Special Session
Clinical Gastric Cancer Clinical
SO-002 Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)
Ian Chau Poster Discussion Special Session
Clinical Gastric Cancer Biomarkers
SO-003 Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results
Ignacio Matos Poster Discussion Special Session
Clinical Other Clinical
SO-004 A phase 1b study of IMU-131 her2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction
Marina Maglakelidze Poster Discussion Special Session
Clinical Gastric Cancer Clinical
SO-005 A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer
Zev Wainberg Poster Discussion Special Session
Clinical Pancreatic Cancer Clinical
SO-006 Hafnium oxide nanoparticles activated by SBRT: a new interventional radiation therapy approach for the treatment of unresectable liver cancers
Thierry De Baere Poster Discussion Special Session
Clinical Hepatocellular Radiation and Imaging
SO-007 Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)
Hiroki Hara Poster Discussion Special Session
Clinical Colon Cancer Clinical
SO-008 Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study
Philippe Cassier Poster Discussion Special Session
Clinical Colon Cancer Clinical
SO-009 Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer
Eric Van Cutsem Poster Discussion Special Session
Clinical Colon Cancer Clinical
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
SO-010 Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors.
Maxim Kebenko Poster Discussion Special Session
Basic Colon Cancer Biomarkers
P-001 Paclitaxel for the treatment of anal cancer after cisplatin and 5-fluorouracil
Kheira Rekai Poster Presentation Clinical Other Metastatic Disease
P-003 Perturbation of fatty acids of erythrocyte membranes and blood serum in patients with colorectal cancer: new opportunities for diagnostics
Margarita Kruchinina Poster Presentation Clinical Colon Cancer Biomarkers
P-004 Nine years of epidemiological changes of gastrointestinal cancer in Egypt
Rasha Aboelhassan Poster Presentation Clinical Other Screening/prevention/epidemiology
P-005 Increased FLVCR1 expression predicts poor prognosis and enhances malignant phenotypes in esophageal squamous cell carcinoma
Suna Zhou Poster Presentation Basic Esophageal Cancer Biomarkers
P-006 miR 381-3p inhibits migration and invasion in ESCC through downregulated FLVCR1
wenguang ye Poster Presentation Basic Esophageal Cancer Biomarkers
P-007 Rectal cancer in Albania: treatment outcome and prognostic factors of disease progression.
Elvisa Kozma Poster Presentation Basic Rectal Cancer Clinical
P-008 Plasma cytokeratin-18 level of patients with esophagogastric cancer as a biomarker of tumour response
Azar Fanipakdel Poster Presentation Basic Gastric Cancer Biomarkers
P-009 Prognostic factors of untreated hepatocellular carcinoma on cirrhosis
STOIAN MARILENA Poster Presentation Basic Hepatocellular Cancer
Clinical
P-010 GLOMERULAR FILTRATION RATE TO LIVER TRANSPLANTATION
P-011 The comparison between UGT1A1 single heterozygous and wild-type regarding the clinical outcomes of fixed-dose irinotecan monotherapy for advanced gastric cancer: a multicenter retrospective study
Takayuki Ando Poster Presentation Clinical Gastric Cancer Metastatic Disease
P-012 Weighted gene co-expression networks explored MiR-92b Implicated In esophageal squamous cell cancer
wanpeng wang Poster Presentation Basic Esophageal Cancer Metastatic Disease
P-013 Surgical and combined treatment for patients with cholangiocarcinoma: the experience of FSBI
Aleksandr Polyakov Poster Presentation Clinical Other Other
P-014 Associations between primary cancer site, metastatic site, comorbidity, and details of symptoms and treatment in advanced gastrointestinal cancer patients at end-of-life
Shuji Hiramoto Poster Presentation Clinical Other Metastatic Disease
P-015 Association between prognosis and discontinuation by image diagnosis for advanced gastrointestinal cancer patients who received end-of-life chemotherapy
Shuji Hiramoto Poster Presentation Clinical Other Radiation and Imaging
P-016 Long-course chemoradiation in carcinoma rectum; is it really worth it? Perspectives from a developing nation
Deep Chakrabarti Poster Presentation Clinical Rectal Cancer Radiation and Imaging
P-017 Place of perioperative chemotherapy at the base of FOLFOX in the treatment of localized gastric cancers: a retrospective study of 31 cases
Sara Jamal Poster Presentation Basic Gastric Cancer Biomarkers
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-018 Prediction of oncologic outcome using systemic neutrophil-to-lymphocyte ratio in stage II and III colon cancer
Youn Young Park Poster Presentation Clinical Colon Cancer Clinical
P-019 Chemotherapeutic hyperthermic intraperitoneal perfusion following radical D2 resection in the treatment of advanced gastric cancer
Lucheng Zhu Poster Presentation Clinical Gastric Cancer Clinical
P-020 Surprisingly high prevalence of DPYD gene mutation in UK regional trust: implications for treatment
Samantha Kestenbaum Poster Presentation Clinical Other Clinical
P-021 Efficient treatment policies and its impact on the economic burden for CRC in low-middle income countries: the Egypt Case.
Abdalla Abotaleb Poster Presentation Clinical Other Other
P-022 Which patients on chemotherapy for colorectal cancer should be anticoagulated?
Mark Hill Poster Presentation Clinical Colon Cancer Clinical
P-025 Toxicity syndromes, patient-related clinical indicator of toxicity burden induced by intensive triplet chemotherapy-based regimens in metastatic gastrointestinal cancers.
Gemma Bruera Poster Presentation Clinical Colon Cancer Metastatic Disease
P-027 Multidirectional colonoscopy quality improvement increases adenoma detection rate: results of the Seoul national university hospital healthcare system Gangnam center colonoscopy quality upgrade project (Gangnam-CUP)
Ji Yeon Seo Poster Presentation Clinical Colon Cancer Screening/prevention/epidemiology
P-028 Long non-coding RNA Linc00525 is an unfavorable prognostic factor and regulates proliferation and apoptosis in colorectal cancer
Peng Peng Poster Presentation Basic Colon Cancer Biomarkers
P-029 Impact on survival of local complications in Pancreatic Cancer: experience at the Ramón y Cajal University Hospital (HURyC)
Juan José Serrano Domingo Poster Presentation Clinical Pancreatic Cancer Clinical
P-030 Serglycin level in peripheral circulating blood cells has prognostic significance in patients with hepatocellular carcinoma
Hongjie Chen Poster Presentation Basic Hepatocellular Cancer
Biomarkers
P-031 Low level of centromere-associated protein E promotes growth of hepatocellular carcinoma and is associated with adverse clinical features
Yiguang Lin Poster Presentation Basic Hepatocellular Cancer
Biomarkers
P-032 Hypofractionated volumetric modulated arc therapy (VMAT) in the treatment of advanced oesophageal cancer.
Letizia Deantonio Poster Presentation Clinical Esophageal Cancer Radiation and Imaging
P-033 Management of small intestine cancers Kheira Rekai Poster Presentation Clinical Other Clinical P-034 PARADIGM study: A multicenter, randomized, phase III study of
mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer
Kei Muro Poster Presentation Clinical Colon Cancer Trials in Progress
P-035 Prognosis of gastric dysplasia according to mucin phenotype after complete resection with endoscopic procedures
Jin-Oh Kim Poster Presentation Clinical Gastric Cancer Clinical
P-036 Multidisciplinary approach associated with improved overall survival in metastatic colorectal cancer
Jolanta Zok Poster Presentation Clinical Colon Cancer Clinical
P-037 Doxycycline as a preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy: interim analysis to evaluate skin toxicities.
Patricia Ramirez Daffos Poster Presentation Clinical Colon Cancer Clinical
P-038 Whole-exome sequencing: 13 primary liver cancer cell lines established in our laboratory
Jun Akiba Poster Presentation Basic Hepatocellular Cancer
Other
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-039 ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: results of a prospective single centre clinical utility study (PRECISE STUDY)
Lennard Lee Poster Presentation Clinical Colon Cancer Clinical
P-040 Cost of metastatic colorectal cancer drugs per month of life gained in Spain
Jose Maria Vieitez de Prado Poster Presentation Clinical Colon Cancer Other
P-041 Predictivity of body mass index, age and tumor laterality for systemic therapy outcome in metastatic colorectal cancer patients
Amer Radwi Poster Presentation Clinical Colon Cancer Clinical
P-042 The clinical outcomes and feasibility of endoscopic full-thickness resection assisted laparoscopic surgery for duodenal neuroendocrine tumor
Jae Young Cho Poster Presentation Clinical Other Surgery
P-043 Scope position is a determining factor for diagnostic performance of EUS-FNA for mass lesions in the pancreas head and uncinate process
Hong Joo Kim Poster Presentation Clinical Pancreatic Cancer Clinical
P-044 Efficacy and safety of early administration of pegfilgrastim in patients with esophageal cancer treated by docetaxel, cisplatin, and 5-fluorouracil (DCF): a phase 2 prospective study
Takeshi Ishikawa Poster Presentation Clinical Esophageal Cancer Clinical
P-045 Long-term results of endoscopic treatment vs. esophagectomy with lymphadenectomy in patients with high-risk early esophageal cancer including detailed analysis of lymph node micrometastases
Julius Spicak Poster Presentation Clinical Esophageal Cancer Clinical
P-046 Expression pattern of death receptors FasR and DR3 on NK and T cells defines the complexity of tumor-immune system interplay in esophageal cancer
Martin Snajdauf Poster Presentation Basic Esophageal Cancer Biomarkers
P-047 Finding the Options of Managing Duodenal Carcinoids in Pakistan. A Retrospective Study in a Tertiary Care Setup
Arooj Fatima Poster Presentation Clinical Other Clinical
P-048 Identifying the Severity of Psychosocial Symptoms among Patients Diagnosed with Gastric Tumors. Do We Really Need Emotional Support Groups?
Arooj Fatima Poster Presentation Basic Gastric Cancer Screening/prevention/epidemiology
P-049 Identifying the nature of perforation in patients diagnosed with gastrointestinal lymphoma. Do we need early interventions?
Arooj Fatima Poster Presentation Clinical Other Clinical
P-050 The Velindre cancer centre experience of panitumumab versus cetuximab in combination with chemotherapy for metastatic colorectal cancer: a comparison of toxicity and economic evaluation.
Amy Case Poster Presentation Clinical Colon Cancer Metastatic Disease
P-051 Predictors of response to 3rd line TAS-102 chemotherapy in metastatic colorectal cancer
Mark Hill Poster Presentation Clinical Colon Cancer Metastatic Disease
P-052 Is there an optimal choice in refractory colorectal cancer? A network meta-analysis
Andrea Casadei Gardini Poster Presentation Clinical Colon Cancer Clinical
P-053 Neoadjuvant rectal cancer (NAR) score as a prognostic factor in locally advanced rectal cancer patients in Assiut university hospital clinical oncology department
Mariam Khalil Poster Presentation Clinical Rectal Cancer Other
P-054 Retrospective analysis of the efficacy and safety of regorafenib in patients with advanced GIST
Hiroshi Nakatsumi Poster Presentation Clinical Other Clinical
P-055 Somatic and germline genetic variants of gastric cancer in Russian patients identified by NGS
Alexey Kalinkin Poster Presentation Basic Gastric Cancer Biomarkers
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-056 Differential expression of CCR5, TIM3 and PD-1 on peripheral blood T and B lymphocytes from hepatitis C patients with hepatocellular carcinoma and their impact on treatment outcomes
P-057 Interleukin-6 correlated with neutrophil-to-lymphocyte ratio in pancreatic cancer
Vlad Pop Poster Presentation Clinical Pancreatic Cancer Biomarkers
P-058 Trifluridine/tipiracil safety and efficacy in Russian patients with metastatic colorectal cancer and refractory or intolerant to standard chemotherapies: Results of the primary analysis.
Mikhail Fedyanin Poster Presentation Clinical Colon Cancer Metastatic Disease
P-059 SM-88 therapy in high-risk poor prognosis pancreatic cancer (PDAC).
Marcus Noel Poster Presentation Clinical Pancreatic Cancer Trials in Progress
P-060 Outcomes for 556 consecutive patients with stages I-III colon cancer managed in a single cancer center in Cyprus over 10 years
Eleni Xenophontos Poster Presentation Basic Colon Cancer Other
P-062 Predicting esophageal cancer outcome with positron emission tomography using deep convolutional neural network
Po-Kuei Hsu Poster Presentation Clinical Esophageal Cancer Other
P-063 ROLE OF MAINTENANCE GEMCITABINE IN ADVANCED AND METASTATIC CARCINOMA GALL BLADDER
manish sharma Poster Presentation Clinical Other Metastatic Disease
P-064 Self-expandable metal stent (SEMS) for esophageal-gastric junction versus pyloric area obstruction in advanced gastric cancer patients: a retrospective, comparative, single-center study
Hee Seok Moon Poster Presentation Clinical Gastric Cancer Other
P-065 A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study
Junichi Nakazawa Poster Presentation Clinical Pancreatic Cancer Metastatic Disease
P-066 Neutrophil/lymphocyte ratio in metastatic colorectal cancer: real-world data for evidence of its prognostic role
Gonçalo Nogueira-Costa Poster Presentation Clinical Colon Cancer Biomarkers
P-067 Can an undifferentiated type early gastric cancer be a candidate for endoscopic resection?
Hyeong Seok Nam Poster Presentation Clinical Gastric Cancer Clinical
P-069 Acute pancreatitis after pressurized intraperitoneal aerosol chemotherapy oxaliplatin in an ongoing phase 1 study for peritoneal metastasis
Guowei Kim Poster Presentation Clinical Other Clinical
P-070 Esophageal cancer: 5 years of experience in a Mexican oncology reference center.
Carlos Salazar-Mejia Poster Presentation Clinical Esophageal Cancer Clinical
P-071 Incidental gallbladder cancer: can we improve survival? Saurabh Galodha Poster Presentation Clinical Other Surgery P-072 Effects of natural substances from Boswellia sacra and Nerium
oleander (breastin) in colon and pancreatic cancer Panagiotis Parsonidis Poster Presentation Basic Colon Cancer Other
P-073 Oxaliplatin-based chemotherapy in patients aged at least 75 years with metastatic colorectal cancer: a post-hoc subgroup analysis if three phase II studies
Gerardo Rosati Poster Presentation Clinical Colon Cancer Metastatic Disease
P-074 A three-year study of epidemiological trends of gastrointestinal cancers in a Haitian cancer program
Doukens Patrick Gilbert Poster Presentation Basic Other Screening/prevention/epidemiology
P-075 SBRT in primary and metastatic liver disease: analysis after implementation in our center
Carolina De la Pinta Poster Presentation Clinical Hepatocellular Radiation and Imaging
P-076 Adjuvant chemotherapy for stage II colon cancer: the prognostic value of high-risk features
Chinock Cheong Poster Presentation Clinical Colon Cancer Clinical
Assigned ID Abstract Title Presenting Author First Name
Younghwan Park Poster Presentation Basic Pancreatic Cancer Other
P-078 Preoperative neutrophil to lymphocyte ratio as a prognostic factor for patients with colorectal cancer
Ivica Zarev Poster Presentation Clinical Colon Cancer Surgery
P-079 Circulating tumor cell detection and microsatellite instability status in predicting outcomes of advanced CRC patients
John Souglakos Poster Presentation Basic Colon Cancer Biomarkers
P-080 Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase II trial (PRODIGE 58 – UCGI 35 – REGIRI)
Emmanuelle Samalin Poster Presentation Clinical Gastric Cancer Trials in Progress
P-081 PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer
John Souglakos Poster Presentation Basic Colon Cancer Biomarkers
P-082 Efficacy and safety of intermittent dosing schedule of apatinib for advanced gastric cancer in second-line setting
Yifu He Poster Presentation Clinical Gastric Cancer Trials in Progress
P-083 FLOT- or CROSS-protocol treatment in advanced adenocarcinoma of the esophagus: a retrospective single-center analysis
Jonas Herzberg Poster Presentation Clinical Esophageal Cancer Clinical
P-085 Rectal adenocarcinoma: clinical predictive factors for tumor response after chemoradiotherapy
Carolina De la Pinta Poster Presentation Clinical Rectal Cancer Radiation and Imaging
P-086 EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment
Muh-Hwan Su Poster Presentation Clinical Pancreatic Cancer Trials in Progress
P-087 Neoadjuvant chemotherapy-induced severe neutropenia predicts favorable histological responses but unfavorable survival in locally advanced gastric cancer
Chaorui Wu Poster Presentation Clinical Gastric Cancer Clinical
P-088 Radiology-guided oesophageal stenting for the palliation of dysphagia: a single center experience
Rajarshi Roy Poster Presentation Clinical Esophageal Cancer Clinical
P-089 FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial
Ana Fernández Montes Poster Presentation Clinical Other Trials in Progress
P-090 North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: final analysis (NORTH/HGCSG1003)
Atsushi Ishiguro Poster Presentation Clinical Colon Cancer Surgery
P-091 Delta-radiomics signature predicts treatment outcomes after preoperative chemoradiotherapy in rectal cancer
Seung Hyuck Jeon Poster Presentation Clinical Rectal Cancer Radiation and Imaging
P-092 Impact on survival of adjuvant chemotherapy following chemo-radiotherapy and surgery in locally advanced, non-metastatic rectal adenocarcinoma: a retrospective analysis among 331 patients
Marion SONDAG Poster Presentation Basic Rectal Cancer Clinical
P-093 Male gender and bone metastases linked to inferior survival in advanced biliary tract cancer
Felipe Oliveira Poster Presentation Clinical Other Metastatic Disease
P-094 KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo-controlled phase 3 study
Hyun Cheol Chung Poster Presentation Clinical Gastric Cancer Trials in Progress
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-095 Gastroenteropancreatic neuroendocrine neoplasia G3 according to 2019 WHO classification: a comprehensive clinicopathological characterization including mismatch repair proteins and PDL1 expression in a large cohort of patients
Julieta Grasselli Poster Presentation Clinical Other Biomarkers
P-096 Pancreatic resection in elderly patients over the age of 70 with primary pancreatic cancer: a retrospective analysis
Elinor Tan Poster Presentation Basic Pancreatic Cancer Surgery
P-097 RGS5 overexpression worsens the prognosis of patients with hepatocellular carcinoma by enhancing cancer cell motility and proliferative activity
Hiroto Fukushima Poster Presentation Basic Hepatocellular Cancer
Biomarkers
P-098 TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)
Pascal Hammel Poster Presentation Clinical Pancreatic Cancer Trials in Progress
P-099 Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients
Emmanuelle Samalin Poster Presentation Clinical Colon Cancer Clinical
P-100 Trifluridine-tipiracil for the treatment of metastatic colorectal cancer patients: UK multicentre real-world experience
Michael Tilby Poster Presentation Clinical Colon Cancer Metastatic Disease
P-101 A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy
Alessandro Parisi Poster Presentation Clinical Gastric Cancer Clinical
P-102 Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin at a dose of 130mg/m2 (nacG-SOX130) in clinical(c)Stage III gastric cancer.
Sayuri Konishi Poster Presentation Clinical Gastric Cancer Clinical
P-103 Prognostic implications of free cancer cells in gastric juice in gastric cancer patients who underwent surgery: a prospective cohort study.
Dai Manaka Poster Presentation Clinical Gastric Cancer Biomarkers
P-104 Potent anticolorectal cancer activity of 5-fluorouracil and laccaic acid combination via modulation of epigenetic regulation
Riya Gupta Poster Presentation Basic Colon Cancer Pre-clinical
P-106 Pristine C60 fullerenes inhibit liver fibrosis and carcinogenesis in rat hepatocellular carcinoma models
Halyna Kuznietsova Poster Presentation Basic Hepatocellular Cancer
Other
P-108 Quality of life assessment and reporting in colorectal cancer: a systematic review of phase III trials published between 2012 and 2018
Pasquale Lombardi Poster Presentation Clinical Colon Cancer Clinical
P-112 A retrospective study on treatment outcomes for patients with high grade neuroendocrine colorectal carcinoma.
Dr Pavlos Piskilidis Poster Presentation Clinical Other Clinical
P-113 Evaluation of the mimetic peptide APOE COG1410 in the viability, migration, and apoptosis of the intestinal cells IEC-18 after injuries by 5-FU
Ticiana Pessoa Poster Presentation Basic Colon Cancer Other
P-114 Relationship between peripheral neuropathy and effectiveness in second-line chemotherapy for unresectable advanced gastric cancer: a prospective, observational, multicenter study protocol
Hiroaki Tanioka Poster Presentation Clinical Gastric Cancer Trials in Progress
P-115 The onset of grade >= 3 neutropenia at the first cycle is associated with longer overall survival in metastatic colorectal cancer patients treated with trifluridine/tipiracil
Jacopo Giuliani Poster Presentation Clinical Colon Cancer Clinical
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-116 GRADE evaluation of the COLOFOL randomized clinical trial Eduardo Ceballos Poster Presentation Clinical Colon Cancer Screening/prevention/epidemiology
P-117 Stage IIa colon cancer: adjuvant chemotherapy in real life Renato Cunha Poster Presentation Clinical Colon Cancer Clinical P-118 Treatment efficacy of endoscopic submucosal dissection for papillary
adenocarcinoma-type early gastric cancer Hee Sung Lee Poster Presentation Clinical Gastric Cancer Clinical
P-121 A SEER analysis of increasing disparities in age-related cause-specific survival (CSS) among patients with colorectal cancer
Tahir Mehmood Poster Presentation Clinical Colon Cancer Clinical
P-122 Advocacy program for GI malignancy patients S vaishali Poster Presentation Clinical Other Other P-123 What do you want me to know about you? A qualitative retrospective
pilot study to pay more attention to patients’ personal life aspects upon admission to a palliative care ward
Anna Kitta Poster Presentation Clinical Other Clinical
P-124 Definitive chemoradiotherapy in oesophageal cancer: treatment outcomes from a regional cancer centre
Mohammed Abdul-Latif Poster Presentation Clinical Esophageal Cancer Clinical
P-125 Total neoadjuvant treatment of “ugly” rectal cancers in Slovenia Vaneja Velenik Poster Presentation Clinical Rectal Cancer Clinical P-126 The management of pancreatic adenocarcinoma in a hospitalized-
based population (2015-2019) aicha bengueddach Poster Presentation Basic Pancreatic Cancer Clinical
P-127 Prognostic value of lymph node ratio in lymph node-invaded colon cancer
Mohamed Elbaiomy Poster Presentation Clinical Colon Cancer Biomarkers
P-128 Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease.
Michele Ghidini Poster Presentation Clinical Colon Cancer Biomarkers
P-129 Expression of female sex hormone receptors, connective tissue growth factor, and HER2 in gallbladder cancer and adjacent normal tissue
Beata Hryciuk Poster Presentation Clinical Other Biomarkers
P-130 Factors associated with the efficacy of aflibercept in patients with metastatic colorectal cancer: results of the multicenter observational study
Mikhail Fedyanin Poster Presentation Clinical Colon Cancer Metastatic Disease
P-131 Cancer immunotherapy with STING agonist and PD-1 immune checkpoint inhibitor effectively suppresses peritoneal carcinomatosis of colon cancer
Chan Kim Poster Presentation Basic Colon Cancer Pre-clinical
P-132 A novel LncRNA (LOC105371049) regulates colorectal cancer proliferation, metastasis and metabolism
hongyan Yu Poster Presentation Basic Colon Cancer Biomarkers
P-133 A randomized, multicenter, open-label controlled phase II trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer
Jan Vermorken Poster Presentation Clinical Colon Cancer Trials in Progress
P-134 Real-world guideline application in the management of pancreatic cancer patients: the Italian GARIBALDI study
Michele Reni Poster Presentation Clinical Pancreatic Cancer Clinical
P-135 Efficacy and safety of apatinib for metastatic colorectal cancer in standard therapy failure
guo sun Poster Presentation Clinical Colon Cancer Clinical
P-136 Effect of regorafenib in delaying definitive deterioration in health-related quality of life across three tumor types
Ralf-Dieter Hofheinz Poster Presentation Clinical Other Clinical
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-137 Circulating T cell subsets differ in PDAC patients at initial diagnosis and after two months of treatment: a single institution prospective study
Skaiste Tulyte Poster Presentation Basic Pancreatic Cancer Biomarkers
P-138 Alcohol consumption and tobacco smoking and selected gastrointestinal cancers morbidity rates in Poland
Miroslaw Jarosz Poster Presentation Basic Other Screening/prevention/epidemiology
P-139 Chemotherapy rechallenge or reintroduction, regorafenib, and TAS-102 for metastatic pretreated colorectal cancer patients: a propensity score analysis of treatment beyond the second line (PROSERpINA Study).
Maria Alessandra Calegari Poster Presentation Clinical Colon Cancer Metastatic Disease
P-140 Correlation between values of specific biomarkers and outcome in metastatic colorectal cancer patients treated with regorafenib
Vincenzo Ricci Poster Presentation Clinical Colon Cancer Biomarkers
P-141 Detecting the disappearance of RAS-mutant clones in the plasma of patients with RAS-mutant mCRC to select patient candidates for anti-EGFR treatment and to monitor resistance to treatment
cristina raimondi Poster Presentation Clinical Colon Cancer Biomarkers
P-142 Sunitinib rechallenge in pancreatic neuroendocrine tumors Vasiliki Michalaki Poster Presentation Clinical Pancreatic Cancer Clinical P-143 Gastric cancer: system approach Oleg Kshivets Poster Presentation Clinical Gastric Cancer Surgery P-144 Impact of ileostomy in the adjuvant treatment of colorectal cancer
stages II-III German Calderillo-Ruiz Poster Presentation Clinical Colon Cancer Other
P-145 Gastric cancer in young Latin women: bad prognostic factors and outcomes.
German Calderillo-Ruiz Poster Presentation Clinical Gastric Cancer Metastatic Disease
P-146 Immune modulatory effects of ibrutinib in pancreatic ductal adenocarcinoma
Meenal Sinha Poster Presentation Clinical Pancreatic Cancer Biomarkers
P-147 Surgery specialization as a prognostic factor in colon cancer German Calderillo-Ruiz Poster Presentation Clinical Colon Cancer Surgery P-148 High rates of hepatocellular carcinoma within two years of starting
treatment for chronic hepatitis C with direct antiviral agents but not with PEG-interferon/ Ribavirin (HORRID Study)
Alexander Siebenhuener Poster Presentation Clinical Hepatocellular Clinical
P-149 OBESITY AND HYPERGLYCEMIA AS A BAD PROGNOSIS FACTOR FOR RECURRENCE AND SURVIVAL IN COLON CANCER.
German Calderillo-Ruiz Poster Presentation Clinical Colon Cancer Clinical
P-150 Perioperative FLOT experience: pathological regression and toxicity Adrián Sánchez Vegas Poster Presentation Clinical Gastric Cancer Clinical
P-151 Circulating tumor cells levels correlate with carcinoembryonic antigen in patients with high-risk colon cancer who experienced disease progression
Emne Abdallah Poster Presentation Basic Colon Cancer Biomarkers
P-152 A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: analysis of Glasgow prognostic score (GPS)
Kazuaki Harada Poster Presentation Clinical Gastric Cancer Metastatic Disease
P-153 Regorafenib in the third-line treatment of metastatic colorectal cancer: a retrospective study of 27 cases
Fatema Zohra Boudinar Poster Presentation Basic Colon Cancer Metastatic Disease
P-154 Correlation between neutrophil/lymphocyte ratio and postoperative infectious complications after pancreatoduodenectomy for carcinoma of the pancreas head
Lucia Romano Poster Presentation Clinical Pancreatic Cancer Biomarkers
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-155 The management of hepatocellular carcinoma: a report of 19 cases Fatema Zohra Boudinar Poster Presentation Basic Hepatocellular Cancer
Clinical
P-156 Treatment for esophageal and esophagogastric junction cancer with radical radiotherapy: a single-institution cohort study
Vesna Bisof Poster Presentation Clinical Esophageal Cancer Radiation and Imaging
P-157 Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen.
Nieves Martínez-Lago Poster Presentation Clinical Colon Cancer Clinical
P-158 Patient understanding of the aim and duration of treatment during the consent process
Gireesh Kumaran Poster Presentation Clinical Other Clinical
P-159 Patterns and predictors of relapse following radical chemoradiotherapy delivered using intensity-modulated radiotherapy with a simultaneous integrated boost in anal squamous cell carcinoma.
Rebecca Muirhead Poster Presentation Clinical Other Clinical
P-160 Updated results of a phase II randomized trial with high dose proton pump inhibitors and metronomic capecitabine as salvage treatment for patients with advanced gastrointestinal tumours
Giulia Arrivi Poster Presentation Clinical Colon Cancer Trials in Progress
P-162 Dose-escalated intensity-modulated radiotherapy (IMRT) using a simultaneous integrated boost (SIB) in rectal cancer
Rebecca Muirhead Poster Presentation Clinical Rectal Cancer Radiation and Imaging
P-163 Whole-exome sequencing of non-metastatic anal squamous cell carcinoma: a prognostic genetic variants analysis
Ismael Ghanem Poster Presentation Basic Other Biomarkers
P-163 Simple endoscopic scoring system for patients with rectal cancer after concurrent chemoradiation therapy
Ho Joon Im Poster Presentation Clinical Rectal Cancer Clinical
P-165 Safety and effectiveness of direct oral anticoagulants for venous thromboembolism in patients with active cancer: a retrospective study
Misato Ogata Poster Presentation Clinical Other Other
P-166 Systemic inflammatory response index (SIRI) predicts poor survival in pancreatic cancer patients treated with FOLFIRINOX
Muhammad Bilal Razzaq Poster Presentation Clinical Pancreatic Cancer Metastatic Disease
P-167 Outcomes of pancreatic adenocarcinoma resection between initial resectable and borderline/unresectable patients undergoing neoadjuvant chemotherapy: a two-center study.
João Moreira-Pinto Poster Presentation Clinical Pancreatic Cancer Clinical
P-168 Maximum tolerated radiation dose for unresectable thoracic esophageal squamous cell carcinoma: both acute and late toxicities matter
Wen Yu Poster Presentation Clinical Esophageal Cancer Clinical
P-169 Apatinib as non-first-line treatment in patients with advanced cholangiocarcinoma.
Jianzhen Lin Poster Presentation Clinical Other Clinical
P-170 Nutritional index differential as a prognostic factor for recurrence in patients with locally advanced rectal cancer
Maritza Ramos-Ramirez Poster Presentation Clinical Rectal Cancer Clinical
P-171 The prognostic effect of immunohistochemical staining of biomarkers
Jaeyoung Kim Poster Presentation Clinical Gastric Cancer Clinical
P-172 Outcomes of laparoscopic liver resection versus percutaneous radiofrequency ablation in patients with hepatocellular carcinoma and liver cirrhosis: 10 years analysis in a single center.
TT Cheung Poster Presentation Clinical Hepatocellular Surgery
P-173 Impact of proteinuria on long-term renal function in patients with gastrointestinal cancer treated with ramucirumab
TAIZO HIRATA Poster Presentation Clinical Other Clinical
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-174 Proposal of optimal cut-off of preoperative serum tumor marker levels to predict postoperative recurrences of gastric cancer
Bin Sato Poster Presentation Clinical Gastric Cancer Biomarkers
P-175 The optimal time interval between self-expandable metallic stent placement and elective operation in patients with obstructive colon cancers: a multicenter retrospective analysis.
Bong-Hyeon Kye Poster Presentation Clinical Colon Cancer Surgery
P-176 Multicenter phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil-resistant advanced gastric cancer (HGCSG1502)
Akira Ueda Poster Presentation Clinical Gastric Cancer Clinical
P-177 Accuracy of clinical staging for rectal cancer Josué Hernández Benitez
Poster Presentation Clinical Rectal Cancer Radiation and Imaging
P-178 A nomogram to predict poor health-related quality of life in metastatic colorectal cancer patients
Vincenzo Formica Poster Presentation Clinical Colon Cancer Clinical
P-179 Retrospective analysis of 18 cases of gastric cancer with peritoneal metastases resulting in successful conversion surgery
Rio Honma Poster Presentation Clinical Gastric Cancer Metastatic Disease
P-180 A phase II study of capecitabine plus oxaliplatin therapy (XELOX) for patients with inoperable/advanced gastric cancer who were resistant/intolerable to fluoropyrimidine, CDDP, taxane, and CPT-11 (OGSG1403)
Junji Kawada Poster Presentation Clinical Gastric Cancer Trials in Progress
P-181 Efficacy of surgical resection in patients with recurrent tumor of intrahepatic cholangiocarcinoma
Junichi Arita Poster Presentation Clinical Hepatocellular Surgery
P-182 Clinical importance of colonoscopy in patients with gastric cancer Hee chan Yang Poster Presentation Clinical Gastric Cancer Clinical P-183 Legumain is a predictive effector of peritoneal metastasis for diffuse
gastric cancer patients Yan wang Poster Presentation Clinical Gastric Cancer Biomarkers
P-184 Calcium and vitamin D intake and colorectal cancer morbidity rates in Poland
Miroslaw Jarosz Poster Presentation Basic Colon Cancer Screening/prevention/epidemiology
P-185 Is intra-arterial hepatic chemotherapy painful? Fouad Kerbage Poster Presentation Basic Colon Cancer Metastatic Disease
P-186 Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers
Michele Simbolo Poster Presentation Basic Other Biomarkers
P-187 A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection
Peter Galle Poster Presentation Basic Hepatocellular Cancer
Trials in Progress
P-188 Hepatic sinusoidal obstruction syndrome (HSOS) in cStage III gastric cancer patients undergoing neoadjuvant chemotherapy with oxaliplatin: a retrospective cohort study
Kiyotaka Kawaguchi Poster Presentation Clinical Gastric Cancer Clinical
P-189 The validity and safety of 1st-line chemotherapy with capecitabine/oxaliplatin for advanced gastric cancer in Japanese patients over 70 years old
Yoshiaki Shindo Poster Presentation Clinical Gastric Cancer Clinical
P-190 Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients
María de Toro Carmena Poster Presentation Clinical Colon Cancer Metastatic Disease
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-191 Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND)
Jorge Aparicio Poster Presentation Clinical Colon Cancer Trials in Progress
P-192 Complete peritonectomy versus selective peritonectomy in peritoneal carcinomatosis secondary to colorectal cancer: a prospective comparative analysis of outcomes
Ashwin KR Poster Presentation Clinical Colon Cancer Metastatic Disease
P-193 FOLFIRINOX after first-line gemcitabine-based chemotherapy in metastatic pancreatic cancer: a mono-institutional experience
Francesca Foschini Poster Presentation Clinical Pancreatic Cancer Metastatic Disease
P-194 Right vs left-sided RAS wild-type metastatic colorectal cancer treated with EGFR inhibitors: prognostic differences
Sílvia Duarte Poster Presentation Basic Colon Cancer Clinical
P-195 Coffee and alcohol consumption and trends in colorectal cancer morbidity in Poland
Miroslaw Jarosz Poster Presentation Basic Colon Cancer Screening/prevention/epidemiology
P-196 Total mesorectal excision for rectal cancer patients: a comparative triple arm study of surgical results in open vs laparoscopic vs robotic-assisted surgery
Ashwin KR Poster Presentation Clinical Rectal Cancer Surgery
P-197 VOYAGER: an open-label, randomised, phase 3 study of avapritinib vs regorafenib in patients with locally advanced metastatic or unresectable gastrointestinal stromal tumour
Sebastian Bauer Poster Presentation Clinical Gastric Cancer Trials in Progress
P-198 Predictors of morbidity and mortality for patients with peritoneal carcinomatosis secondary to colorectal cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Ashwin KR Poster Presentation Clinical Colon Cancer Metastatic Disease
P-199 Role of robotic surgery for rectal cancer: short-term, functional, and oncological outcomes for 150 consecutive patients
Ashwin KR Poster Presentation Clinical Rectal Cancer Surgery
P-200 Assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer
Ashwin KR Poster Presentation Clinical Hepatocellular Other
P-201 Treatment of relapsed oesophagogastric adenocarcinoma after perioperative chemotherapy and surgery
Michael Davidson Poster Presentation Clinical Gastric Cancer Metastatic Disease
P-202 Search for new predictive/prognostic biomarkers in potentially resectable pancreatic ductal adenocarcinoma
Iranzu González Borja Poster Presentation Clinical Pancreatic Cancer Biomarkers
P-203 The role of combined treatment of metastatic colorectal cancer in patients with liver metastases
Danila Gridnev Poster Presentation Clinical Colon Cancer Metastatic Disease
P-204 Procalcitonin can be used to predict not only postoperative infectious complications but also prognosis in colorectal cancer patients
Junghoon Bae Poster Presentation Clinical Colon Cancer Biomarkers
P-205 Hepatocellular carcinoma: characteristics, outcomes, and prognostic fators
P-210 Cytosponge™ for post chemoradiation surveillance of oesophageal cancer: a feasibility study
Somnath Mukherjee Poster Presentation Clinical Esophageal Cancer Trials in Progress
P-211 A nomogram to predict neutropenia in metastatic pancreatic cancer patients treated with gemcitabine/nab-paclitaxel
Cristina Morelli Poster Presentation Clinical Pancreatic Cancer Clinical
P-212 The use of oral capecitabine with irinotecan and cetuximab (mCAPIRI-C) among colorectal cancer patients with unresectable liver-only metastases
SM Wong Poster Presentation Clinical Colon Cancer Metastatic Disease
P-213 CA19-9 decrease and predictive value for response in patients with metastatic pancreatic cancer treated with FOLFIRINOX
José Francisco Rodríguez Hernández
Poster Presentation Clinical Pancreatic Cancer Biomarkers
P-214 Does PICC side matter? The experience at our hospital Ana Gil Torralvo Poster Presentation Clinical Other Clinical P-215 Recurrence rate in colorectal adenocarcinoma patients receiving
adjuvant capecitabine monotherapy: do the number of chemotherapy cycles and relative dose intensity of the drug play a role?
Joseph Sgouros Poster Presentation Clinical Colon Cancer Clinical
P-216 Neo-adjuvant Chemo-Radiation for Resectable Esophageal Carcinoma – is Oral Capecitabine Non-Inferior to Paclitaxel – Carboplatin Combination?
Aloke Ghosh Dastidar Poster Presentation Clinical Esophageal Cancer Clinical
P-217 A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2
Peter Galle Poster Presentation Basic Hepatocellular Cancer
Trials in Progress
P-218 L1CAM expression in colorectal cancer identifies patients prone to metastasis already in early-stage disease
Athanasios Tampakis Poster Presentation Basic Colon Cancer Biomarkers
P-219 Is there any affordable and reliable score in local gastric cancer? Antía Cousillas Castiñeiras
Poster Presentation Clinical Gastric Cancer Biomarkers
P-220 Perioperative chemotherapy with FLOT vs other regimens for resectable gastric cancer
Tamar Esakia Poster Presentation Clinical Gastric Cancer Trials in Progress
P-221 Locally advanced unresectable or metastatic pancreatic adenocarcinoma in patients under 65 years with good performance status (PS) at Ramón y Cajal University Hospital in Madrid
Roberto Martín Huertas Poster Presentation Clinical Pancreatic Cancer Clinical
P-222 Patient-reported outcomes including LARS score and quality of life one year after chemoradiotherapy for anal cancer
Karen-Lise Spindler Poster Presentation Clinical Other Clinical
P-223 Quality of life and preoperative chemotherapy in gastric cancer in Chile: results from the observational study of perioperative chemotherapy in gastric cancer (PRECISO)
Bettina Mueller Poster Presentation Clinical Gastric Cancer Clinical
P-224 Phase 2 HEPANOVA trial of tumor treating fields concomitant with sorafenib for advanced hepatocellular carcinoma
Uri Weinberg Poster Presentation Clinical Hepatocellular Trials in Progress
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-225 Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial
Milind Javle Poster Presentation Clinical Other Trials in Progress
P-226 Efficacy of first-line systemic therapy for left-sided primary metastatic colon cancer: a single-centre retrospective cohort analysis of 186 patients
Juraj Prejac Poster Presentation Clinical Colon Cancer Metastatic Disease
P-227 Real World Data (RWD) of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): clinical benefit from a Spanish single institution.
Alberto Sánchez-Camacho
Poster Presentation Clinical Colon Cancer Clinical
P-228 Tumor Treating Fields (150 kHz) combined with FOLFOX inhibits gastric cancer in vitro
Moshe Giladi Poster Presentation Basic Gastric Cancer Pre-clinical
P-229 The value of alfa-fetoprotein and neutrophil/lymphocyte ratio (NLR) in the prognosis of patients with hepatocellular carcinoma
P-230 EFFECTIVENESS OF CA 19.9 IN PREDICTING PROGNOSIS IN METASTATIC PANCREATIC CANCER PATIENTS TREATED WITH NAB-PACLITAXEL PLUS GEMCITABINE
Stefano Mariani Poster Presentation Clinical Pancreatic Cancer Biomarkers
P-231 Proinflammatory cytokines as predictive factors for response to chemotherapy or mental disorders present in colorectal cancer patients
Claudia Burz Poster Presentation Clinical Colon Cancer Clinical
P-232 RENCA MACROBEAD THERAPY (RMB): A BIOLOGICAL-SYSTEMS APPROACH TO METASTATIC COLORECTAL CANCER [U.S. FDA BB-IND 10091]
Angelica Nazarian Poster Presentation Clinical Colon Cancer Trials in Progress
P-233 Disparities in clinical outcomes across age, sex and race among patients with pancreatic adenocarcinoma: a single center experience
Ravi Paluri Poster Presentation Clinical Pancreatic Cancer Screening/prevention/epidemiology
P-234 The T cell architecture of pancreatic ductal adenocarcinoma Shivan Sivakumar Poster Presentation Basic Pancreatic Cancer Clinical P-235 Induction Chemotherapy with Taxane versus Anthracycline-based
Triplet for Locally Unresectable Nonmetastatic Gastric Cancer Clara Borges Poster Presentation Clinical Gastric Cancer Clinical
P-236 Histological Patterns and Clinical Characteristics of Metastatic Gastric Adenocarcinoma, Single institutional Experience in The Eastern Province of Saudi Arabia
Nedal Bukhari Poster Presentation Clinical Gastric Cancer Metastatic Disease
P-237 Does metastatic colorectal cancer in elderly patients have specific features: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment?
Andrija Katic Poster Presentation Clinical Colon Cancer Biomarkers
P-238 Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Lorenza Rimassa Poster Presentation Clinical Hepatocellular Trials in Progress
P-239 Sorafenib for advanced hepatocellular carcinoma (HCC) in the public health setting in Brazil: a cost-effectiveness analysis
Andre Sasse Poster Presentation Clinical Hepatocellular Other
P-240 Outcomes of Gastrointestinal cancers treated on Phase 1 clinical trials at O’Neal Comprehensive Cancer Center
Ravi Paluri Poster Presentation Clinical Other Clinical
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-241 Epidemiological study of gall bladder cancer Boudjella Abdelkader El Hakim
Poster Presentation Basic Other Screening/prevention/epidemiology
P-242 PREVENTING ORAL MUCOSITIS BY USING ITS CHRONOLOGY IN PRIOR CYCLE AND A SPECIAL MOUTHWASH
Esther Una Cidon Poster Presentation Clinical Pancreatic Cancer Clinical
P-243 A comparison of the utilization and efficacy of palliative chemotherapy for the treatment of locally advanced or metastatic gastroesophageal carcinoma: a retrospective single-center analysis
Aysegül Ilhan-Mutlu Poster Presentation Clinical Gastric Cancer Metastatic Disease
P-244 Therapeutic aspects of gallbladder cancer Boudjella Abdelkader El Hakim
Poster Presentation Clinical Other Other
P-245 Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy for patients with locally advanced pancreatic cancer
Ravi Paluri Poster Presentation Clinical Pancreatic Cancer Trials in Progress
P-246 The importance of laterality in colorectal cancer predicting response to therapeutics – retrospective study evaluating differences between right and left colon in stage IV colon cancer
Élia Cipriano Poster Presentation Clinical Colon Cancer Metastatic Disease
P-247 SPLACHNIC VEIN THROMBOSIS IN CHOLANGIOCARCINOMA. A RETROSPECTIVE OBSERVATIONAL STUDY. DONOSTIA UNIVERSITARY HOSPITAL.
Ana Landa Poster Presentation Clinical Other Clinical
P-248 Futility and Utility of Two-stage Hepatectomy Miguel Cunha Poster Presentation Clinical Colon Cancer Metastatic Disease
P-249 Right-sided versus left-sided metastatic Colorectal Cancer Wala Ben Kridis Poster Presentation Basic Colon Cancer Clinical P-250 The combined treatment of 150 kHz Tumor Treating Fields (TTFields)
and Sorafenib shows In vitro and in vivo efficacy in hepatocellular carcinoma
Moshe Giladi Poster Presentation Basic Pancreatic Cancer Pre-clinical
P-251 FLOT versus ECF/ECX peri-operative regimens in real life setting for patients with resectable gastric adenocarcinoma
Joana Graça Poster Presentation Clinical Gastric Cancer Clinical
P-252 GEMCITABINE INDUCED HAEMOLYTIC UREMIC SYNDROME: THE BIG UNKNOWN
Esther Una Cidon Poster Presentation Clinical Pancreatic Cancer Clinical
P-253 Age vs Performance Status - What is worst for surgery outcome? Edgar Amorim Poster Presentation Clinical Colon Cancer Surgery P-254 LIQUID BIOPSY FOR RAS MUTATIONAL STATUS ANALYSIS IN
METASTATIC COLORETAL CANCER Joana Marinho Poster Presentation Clinical Colon Cancer Clinical
P-255 Outcomes of treatment for non-metastatic rectal cancer; ten years single institute experience at the Bank of Cyprus Oncology Centre (BOCOC)
Ifigenia Konstantinou Poster Presentation Clinical Rectal Cancer Clinical
P-256 Locally advanced unresectable and metastatic pancreatic cancer – predictors of survival
Élia Cipriano Poster Presentation Clinical Pancreatic Cancer Other
P-257 Singe center experience of treatment gastric cancer with liver met’s. Farrukh Djuraev Poster Presentation Clinical Gastric Cancer Metastatic Disease
P-258 Computational simulations to determine effectiveness and thermal safety of tumor treating fields’ delivery to the abdomen
Ze'ev Bomzon Poster Presentation Basic Pancreatic Cancer Radiation and Imaging
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-259 A novel anti-tumorigenic mechanism by herbal extract saikosaponin-d through p-STAT3/C/EBPβ signaling suppression of COX-2 in liver cancer
Yiguang Lin Poster Presentation Basic Hepatocellular Cancer
Pre-clinical
P-260 PANOVA-3: A phase 3 study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC).
Uri Weinberg Poster Presentation Clinical Pancreatic Cancer Trials in Progress
P-261 Poor Prognosis of Hypermutant Colorectal Cancer with KRAS mutations: A Retrospective Analysis of 1,052 Japanese Colorectal Cancer Patients without Treatment of Immuno-checkpoint Inhibitors.
Takeshi Nagasaka Poster Presentation Basic Colon Cancer Biomarkers
P-262 Percutaneous transhepatic biliary drainage in malignant biliary obstruction: complications and outcome
Manoj Kumar Poster Presentation Clinical Other Other
P-263 Over-expression of c-MET in Biliary Tract Cancer. Prevalence and Clinical-Molecular Correlation.
Rodrigo Segovia Poster Presentation Clinical Other Biomarkers
P-264 Chinese herbal medicine Sijunzi decoction alleviates liver cancer cachexia through downregulating TGF-β and IGF 1 signaling pathways
Yan Chen Poster Presentation Basic Hepatocellular Cancer
Pre-clinical
P-265 RETROPERITONEAL LYMPH NODE METASTASES AS A PROGNOSIS FACTOR IN OVERALL SURVIVAL IN METASTATIC COLORECTAL CANCER
German Calderillo-Ruiz Poster Presentation Clinical Colon Cancer Metastatic Disease
P-266 Metastatic pancreatic cancer: Characteristics of long-term survivors Vincent Picozzi Poster Presentation Clinical Pancreatic Cancer Metastatic Disease
P-267 Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer
Tatiana Titova Poster Presentation Basic Gastric Cancer Metastatic Disease
P-268 Association between primary perioperative CEA ratio, tumor site, and overall survival in patients with colorectal cancer
Anup Kasi Poster Presentation Clinical Colon Cancer Clinical
P-269 PIPAC PACLITAXEL: A SYSTEMATIC AND PERITONEAL TISSUE PHARMACOKINETIC STUDY IN SWINE
Hon Lyn Tan Poster Presentation Basic Other Pre-clinical
P-271 Efficacy and tolerability of combination of Liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic cancers: post-approval clinic experience .
Ravi Paluri Poster Presentation Clinical Pancreatic Cancer Clinical
P-272 Is the gastroenterologist really necessary in the operating room? Intraoperative rectosigmoidoscopy: how we do it.
Edgar Amorim Poster Presentation Clinical Other Surgery
P-273 MINI INVASIVE INTERVENTIONS IN ACUTE HOLANGITE MALIGNANT AND BENIGN ETIOLOGY
Ilkhom Tashbulov Poster Presentation Clinical Other Surgery
P-274 A MULTICENTER SPANISH RETROSPECTIVE STUDY OF PLATINUM BASED CHEMOTHERAPY SENSITIVITY IN THE FIRST LINE SETTING AFTER RELAPSE FROM PERIOPERATIVE PLATINUM BASED CHEMOTHERAPY IN GASTRIC CANCER.
Luis del Carpio Poster Presentation Clinical Gastric Cancer Clinical
P-275 Immune-inflammatory and clinicopathologic prognostic factors in a Western cohort of resected gastric cancers (GCs)
Massimiliano Salati Poster Presentation Clinical Gastric Cancer Clinical
P-276 Neoantigen-reactive T cells combined with chemotherapy and radiation improved survival in advanced pancreatic cancer
Qin Liu Poster Presentation Clinical Pancreatic Cancer Clinical
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-277 Socioeconomic and Administrative Factors Associated with Health care Delay and Treatment of Esophageal and Gastric Carcinoma: Experience at a Tertiary Care Centre in a Developing Country
SYED HASSAN Poster Presentation Basic Esophageal Cancer Screening/prevention/epidemiology
P-279 Characterization of mismatch repair deficiency in biliary tract cancer Caterina Vivaldi Poster Presentation Basic Other Biomarkers
P-280 Clinicopathologic difference according to gender in gastric cancer Sanghoon Han Poster Presentation Clinical Gastric Cancer Clinical P-281 EFFICACY OF A THERAPEUTIC EXERCISE PROGRAM ON
AUTONOMIC NERVOUS SYSTEM FUNCTION, CARDIAC FUNCTION AND FUNCTIONAL CAPACITY IN COLORRECTAL CANCER SURVIVORS: A RANDOMIZED CONTROLLED PILOT STUDY
Julia Ruiz-Vozmediano Poster Presentation Clinical Colon Cancer Screening/prevention/epidemiology
P-282 Is additive treatment necessary for patients with a positive lateral margin after endoscopic submucosal dissection of early gastric cancer?
Young Sin Cho Poster Presentation Clinical Gastric Cancer Clinical
P-283 Predictors of Oxaliplatin-Induced Hepatotoxicity: Increase in Spleen Volume or Liver Fibrosis and Steatosis?
Malek Kreidieh Poster Presentation Clinical Other Clinical
P-284 Gevokizumab, an interleukin-1β (IL-1β) monoclonal antibody (mAb), in metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC) and metastatic renal cell carcinoma (mRCC): “first-in-cancer” phase Ib study
Eric Van Cutsem Poster Presentation Clinical Other Trials in Progress
P-285 The role of active nutritional intervention in patients receiving chemoradiation (CRT) for oesophageal cancer
Robert Owens Poster Presentation Clinical Esophageal Cancer Other
P-286 The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with FIRST-LINE NAB-PACLITAXEL AND GEMCITABINE: POST-HOC ANALYSIS OF an Austrian multicenter, non-interventional study
Jakob Riedl Poster Presentation Clinical Pancreatic Cancer Biomarkers
P-287 Compression therapy of both hands is safely applicable for the prevention of oxaliplatin induced neuropathy.
Michina Morioka Poster Presentation Clinical Colon Cancer Clinical
P-288 The role of sideness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA)
Debora Basile Poster Presentation Clinical Colon Cancer Metastatic Disease
P-289 Incidence and severity of cancer-related fatigue in gastric cancer patients
Bogdan Gafton Poster Presentation Clinical Gastric Cancer Clinical
P-290 Comparative analyses between younger and older patients with pancreatic adenocarcinoma: differences in clinicopathological features, treatment patterns and outcomes
Mohamed Salem Poster Presentation Clinical Pancreatic Cancer Metastatic Disease
P-291 NRG1-fusion positive gastrointestinal tumours: Afatinib as a novel potential treatment option
Benjamin Weinberg Poster Presentation Clinical Other Clinical
P-292 Prognostic role white blood cell levels in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy
Stamatina Demiri Poster Presentation Clinical Pancreatic Cancer Biomarkers
P-293 EVALUATION OF NEOANGIOGENESIS IN LOCALLY ADVANCED GASTRIC CANCER BEFORE AND AFTER NEOADIUVANT RADIOCHEMOTHERAPY BY PROBE CONFOCAL LASER ENDOMICROSCOPY (PCLE)
Renato Cannizzaro Poster Presentation Clinical Gastric Cancer Radiation and Imaging
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-294 Role of chemoradiation (CRT) in the adjuvant treatment of radically resected pancreatic cancer (PC) patients (pts): a mono-institutional retrospective analysis
Lisa Salvatore Poster Presentation Clinical Pancreatic Cancer Radiation and Imaging
P-295 Endoscopic Submucosal Dissection using An Detachable Robotic Assitive Device in a live porcine model
Se Hyun Jang Poster Presentation Clinical Gastric Cancer Surgery
P-296 Overall survival and progression free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience.
Andrea Pretta Poster Presentation Basic Colon Cancer Metastatic Disease
P-297 Serum level of miRNA-143 as a potential prognostic marker in patients with colorectal cancer and synchronous metastatic disease
Antoan Garev Poster Presentation Basic Colon Cancer Biomarkers
P-298 Directed differentiation of human pluripotent stem cells into hepatic tissue with gallbladder and bile ducts organoids in vitro
Fenfang Wu Poster Presentation Basic Hepatocellular Cancer
Other
P-299 Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients
Silvia Catanese Poster Presentation Clinical Gastric Cancer Radiation and Imaging
P-300 Pancreatic Cancer resection in elderly patients: Analysis of outcomes
Angel Cuadrado-García Poster Presentation Clinical Pancreatic Cancer Surgery
P-301 Tumor mutation burden and microsatellite instability in colorectal cancer
Francesca Fenizia Poster Presentation Clinical Colon Cancer Biomarkers
P-302 Prospective Evaluation of FOLFIRINOX in Neo-adjuvant Treatment of Gastro-Oesophageal Junction Carcinomas
Andrew Dean Poster Presentation Clinical Esophageal Cancer Surgery
P-303 Third-line re-treatment of advanced pancreatic adenocarcinoma with gemcitabine and nab-paclitaxel
Adarsh Das Poster Presentation Clinical Pancreatic Cancer Clinical
P-304 Modified FOLFIRINOX as a second-line treatment in pancreatic adenocarcinoma following gemcitabine plus nab-paclitaxel failure in patients with performance status two or less
Andrew Dean Poster Presentation Clinical Pancreatic Cancer Clinical
P-305 K-Ras mutation in liquid biopsy and tumor tissue correlation in patients with pancreatic cancer
Eduardo Perdomo Zaldivar Poster Presentation Clinical Pancreatic Cancer Biomarkers
P-306 Anal cancer outcomes and human immunodeficiency virus: a single-center experience
Carmen Garcia Duran Poster Presentation Clinical Other Clinical
P-307 Epidemiology, treatment and prognostic factors of colorectal cancers in Tunisia: compliance with recommendations and therapeutic results
ABDERRAZEK HADDAOUI Poster Presentation Clinical Colon Cancer Clinical
P-308 role of TILS in predicting evolution of metastatic colorectal cancer ABDERRAZEK HADDAOUI Poster Presentation Basic Colon Cancer Metastatic Disease
P-309 Molecular and Pathological Features in Patients with Gastric Cancer in Argentina. Association between Epstein Barr Virus, MSI, PD-L1 expression and T-cells infiltration.
Mirta Kujaruk Poster Presentation Clinical Gastric Cancer Biomarkers
P-310 Efficacy of FOLFIRI as a second-line in extrapulmonary poorly-differentiated neuroendocrine carcinoma.
Carles Fabregat Franco Poster Presentation Clinical Other Metastatic Disease
P-311 Defining a new standard of preoperative chemoradiation in operable stomach cancers
Y Susheel Kumar Poster Presentation Clinical Gastric Cancer Radiation and Imaging
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-312 The survival of patients with pancreatic cancer in Jeju Island may be related to blood type.
Sanghoon Han Poster Presentation Clinical Pancreatic Cancer Clinical
P-313 Chemoradiation with capecitabine and mitomycin-C for locally advanced anal squamous cell carcinoma: experience of a single portuguese institution
Isalia Miguel Poster Presentation Clinical Other Clinical
P-314 Do we need adjuvant therapy in patients with rectal cancer and pathologic complete response, after conventional preoperative chemoradiation and laparoscopic (LapTME) or Transanal total mesorectal excision (TaTME)?
Roxana Reyes Poster Presentation Clinical Rectal Cancer Clinical
P-315 ΔNp73 and Δ133p53 in liquid biopsy as early diagnostic markers for colorectal cancer
Javier Rodriguez-Cobos Poster Presentation Basic Colon Cancer Biomarkers
P-316 Outcomes of gastrointestinal tumours in the tyrosine kinase inhibitor era: 15 years of experience from a single tertiary care centre in India.
PRABHAT BHARGAVA Poster Presentation Clinical Other Clinical
P-317 Clinical, pathological, and prognostic features of rare BRAF mutations in metastatic colorectal cancer: a bi-institutional retrospective analysis (REBUS study)
Maria Bensi Poster Presentation Clinical Colon Cancer Metastatic Disease
P-318 The role of interleukin-8 (IL-8) in predicting outcome of metastatic colorectal cancer patients treated with aflibercept in combination to FOLFIRI: the FLIBER study
Manolo D'Arcangelo Poster Presentation Basic Colon Cancer Trials in Progress
P-319 Longitudinal evaluation of angiogenesis-related circulating biomarkers during second-line treatment with paclitaxel and ramucirumab in advanced gastro-esophageal cancer
Lorenzo Fornaro Poster Presentation Basic Gastric Cancer Biomarkers
P-320 Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: real world data of 13 oncological centers in Portugal
Tiago Tomás Poster Presentation Clinical Colon Cancer Metastatic Disease
P-321 Young onset rectal cancer: a therapeutic challenge Debapriya Mondal Poster Presentation Clinical Rectal Cancer Clinical P-322 CHANGES IN THE EXCHANGE OF MINERALS DURING
MECHANICAL JUNDICE OF TUMOR ETIOLOGY Ilkhom Tashbulov Poster Presentation Clinical Other Surgery
P-323 Is always necessary FNA in submucosal lesion miming GIST? Renato Cannizzaro Poster Presentation Clinical Gastric Cancer Radiation and Imaging
P-324 Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Experience
Rojymon Jacob Poster Presentation Clinical Pancreatic Cancer Clinical
P-325 Outcomes of combined modality neo-adjuvant chemo-radiotherapy (CRT) and surgery in resectable esophageal carcinoma patients treated at a tertiary cancer care centre.
Sidharth Pant Poster Presentation Clinical Esophageal Cancer Radiation and Imaging
P-326 CLINICAL PRACTICE USE OF LIQUID BIOPSY TO IDENTIFY RAS/BRAF MUTATIONAL STATUS IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A SINGLE INSTITUTION EXPERIENCE
Vincenzo De Falco Poster Presentation Clinical Colon Cancer Biomarkers
P-327 Exploration of alternative regorafenib regimens to manage hand-foot-skin-reaction
Adriaan Cleton Poster Presentation Clinical Colon Cancer Clinical
P-328 Treatment of Metastatic Colorectal Cancer in the Real World (mCRC): Final Results from a European Survey
Zorana Maravic Poster Presentation Basic Colon Cancer Metastatic Disease
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-329 Gemcitabine-based chemotherapy after FOLFIRINOX: a Portuguese retrospective multicenter analysis
Maria Neves Poster Presentation Clinical Pancreatic Cancer Clinical
P-330 Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data
Pasquale Vitale Poster Presentation Clinical Colon Cancer Clinical
P-331 Paclitaxel plus ramucirumab combination therapy as second-line therapy in elderly patients with metastatic advanced gastric cancer ; A single center retrospective study.
Tomomi Kashiwada Poster Presentation Clinical Gastric Cancer Metastatic Disease
P-332 A new prognostic score for biliary tract cancer: a multicenter experience
Pina Ziranu Poster Presentation Clinical Other Clinical
P-333 Early fluorescence detection oropharengeal and esophageal cancer Rasul Sadykov Poster Presentation Clinical Esophageal Cancer Surgery
P-334 Functionalized nanoparticles as tools in anti-cancer treatment Magdalena Kędzierska Poster Presentation Basic Other Other P-335 FOLFIRINOX versus Nab-paclitaxel plus gemcitabine in the first-line
chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: a multivariate analysis of prognostic factors in a national cohort (Comunica-TTD working group).
Federico Longo Muñoz Poster Presentation Clinical Pancreatic Cancer Metastatic Disease
P-336 Retrospective study of TAS-102 plus bevacizumab for patients with metastatic colorectal cancer in salvage therapy
ATSUSHI HISAMATSU Poster Presentation Clinical Colon Cancer Metastatic Disease
P-337 Prospective clinical study phase IIa open label and not randomized of efficacy and toxicity of weekly paclitaxel chemotherapy in patients with advanced esophagogastric adenocarcinoma.
Consuelo Diaz Poster Presentation Clinical Esophageal Cancer Clinical
P-338 Liver resection in elderly patients over the age of 70 with primary liver cancer: A retrospective analysis
Elinor Tan Poster Presentation Basic Hepatocellular Cancer
Surgery
P-339 Epidemiology, treatment modalities and prognostic factors of colon cancer in the central region of Tunisia
Imtinene Belaid Poster Presentation Clinical Colon Cancer Metastatic Disease
P-340 Higher expression of ERBB2, KRAS and down-regulation of APC, NF1 genes in colorectal cancer
Humaira Muzaffar Poster Presentation Basic Colon Cancer Other
P-341 Health disparities and gastric cancer survival in Cali, Colombia: a hospital-based study
Angela Zambrano Poster Presentation Clinical Gastric Cancer Screening/prevention/epidemiology
P-342 Impact of KRAS mutations in clinical features and survival in pancreatic cancer patients: a single institution experience.
Elizabeth Inga Poster Presentation Clinical Pancreatic Cancer Clinical
P-343 Association of Prognostic Nutritional Index as a predictive factor of survival in patients with colorectal cancer in a Mexican population.
Consuelo Diaz Poster Presentation Clinical Colon Cancer Clinical
P-344 Survival analysis of gastric cancer in a Hispanic population: 15-years of experience at a specialized cancer center
Angela Zambrano Poster Presentation Clinical Gastric Cancer Clinical
P-345 Turnaround time < 7 days with a fully automated assay for RAS mutations in metastatic colorectal cancer: a pilot project in real-life conditions
Stéphane ROSSAT Poster Presentation Basic Colon Cancer Biomarkers
P-346 A single center experience with oral chemotherapy with capecitabine and temozolomide in metastatic neuroendocrine tumors
Ines Rego Poster Presentation Clinical Other Metastatic Disease
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-347 THE RISK OF HEPATITIS B VIRUS (HBV) REACTIVATION IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) UNDER IMATINIB MESYLATE TREATMENT
GEORGIA LAZARAKI Poster Presentation Clinical Other Clinical
P-348 Esophageal cancer: about 42 cases Experience of the medical oncology department of Hassan II University Hospital of Fez, Morocco
Karima Oualla Poster Presentation Basic Esophageal Cancer Other
P-349 The Epidemiology of Pancreatic Cancer in Ukraine Liliia Zrielykh Poster Presentation Clinical Pancreatic Cancer Screening/prevention/epidemiology
P-350 Management of gallbladder cancer - EXPERIENCE OF MEDICAL ONCOLOGY DEPARTMENT ABOUT 140 CASES
Karima Oualla Poster Presentation Basic Hepatocellular Cancer
Other
P-351 Pancreatic Cancer Europe Heatmap: A comparative presentation of inequalities
Nuria Malats Poster Presentation Basic Pancreatic Cancer Other
P-352 Prognostic Value, Clinicopathologic Features and Diagnostic Accuracy of Interleukin-8 in Colorectal Cancer: A prospective study in 60 patients in Tunisia.
ABDERRAZEK HADDAOUI Poster Presentation Clinical Colon Cancer Clinical
P-353 Neurotoxicity of oxaliplatin in patients treated for colorectal cancer: FOLFOX versus XELOX
Hanane Fatima Zahra
Aliane Poster Presentation Clinical Colon Cancer Clinical
P-354 Survival and prognostic factors of localized gastric carcinomas (about 50 cases) Experience of the medical oncology department of Hassan II university of fez
Hayat Erraichi Poster Presentation Clinical Gastric Cancer Clinical
P-355 To investigate the role of PGD2 and its receptor signalling in colon cancer pathophysiology
Pujarini Dash Poster Presentation Basic Colon Cancer Other
P-356 COLORECTAL CANCER IN YOUNG TUNISIAN PATIENTS: clinical, histopathological and RAS testing data
Hayfa GUETTITI TOUNSI
Poster Presentation Basic Colon Cancer Screening/prevention/epidemiology
P-357 The place of oncogeriatric evaluation in the therapeutic management and the prediction of the toxicity of the specific medical treatment of elderly patients with colorectal cancer
Hanane Fatima Zahra
Aliane Poster Presentation Clinical Colon Cancer Clinical
P-358 Simultaneous lungs and liver resections in metastatic colorectal cancer patients
Olena Kolesnik Poster Presentation Clinical Colon Cancer Surgery
P-359 Simultaneous resection for neuroendocrine tumors with synchronous liver metastases (SNTLM)
Andrii Lukashenko Poster Presentation Clinical Other Surgery
P-360 Pancreatic neuroendocrine tumors Nataliia Chorna Poster Presentation Clinical Other Surgery P-361 Laparoscopic liver resection in metastatic colorectal cancer Yuriy Ostapenko Poster Presentation Clinical Colon Cancer Surgery P-362 Reasons for chemotherapy discontinuation and end of life in gastro-
intestinal cancers: a multicentric prospective AGEO study Solene Doat Poster Presentation Clinical Other Clinical
P-363 Gallbladder cancer in Morocco: the epidemiological evidence Hinde Hami Poster Presentation Basic Other Screening/prevention/epidemiology
P-364 High expression of estrogen receptor beta correlates with anti-tumorigenic and anti-proliferative inflammatory proteins in colorectal cancer patients
Geriolda Topi Poster Presentation Basic Colon Cancer Other
P-365 Baseline 18F-FDG-PET and Dynamic Contrast Enhanced (DCE)-MRI for assessment of lymph node metastatic potential of oesophageal adenocarcinoma.
Kasia Owczarczyk Poster Presentation Clinical Esophageal Cancer Biomarkers
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-366 Diagnostic and prognostic value of P53 and the human Programmed cell death 4 (PDCD-4) genes in colorectal cancer
Enas Elkhouly Poster Presentation Basic Colon Cancer Biomarkers
P-367 Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in malignant peritoneal disease: a review on outcomes for colorectal cancer
Joana Simões Poster Presentation Clinical Other Other
P-368 Chemoradiation and surgery versus chemoradiation followed by neoadjuvant chemoterapy and surgery in locally advanced rectal cancer: a retrospective analysis of a single center experience
Bárbara Lima Poster Presentation Clinical Rectal Cancer Clinical
P-369 Home chemotherapy in colorectal cancer: First experience in Argentina
guillermo streich Poster Presentation Clinical Other Other
P-370 Role of radiotherapy in local control of metastatic rectal cancer: a single-center experience
Ana Afonso Poster Presentation Clinical Rectal Cancer Radiation and Imaging
P-371 Feasibility of modulated electro-hyperthermia as a concomitant boost to preoperative radiotherapy in locally-advanced rectal cancer: A phase 2 trial
Seihwan You Poster Presentation Clinical Colon Cancer Clinical
P-372 WNT / β-CATENIN PATHWAY IN RECOVERING IEC-6 INTESTINAL CELLS AFTER 5-FU INDUCED INJURY AND TREATMENT WITH MIMETIC PEPTIDE APOE COG133.
Ticiana Pessoa Poster Presentation Basic Colon Cancer Other
P-374 Krukenberg tumors arising from gastric cancer: a report of 6 cases Kawthar Messoudi Poster Presentation Basic Gastric Cancer Clinical
P-375 Palliative management of malignant bilary obstruction in patients with advanced biliary tract cancers
P-376 Primary malignant tumors of the small intestine: clinical and therapeutic aspects
Karima Oualla Poster Presentation Clinical Other Clinical
P-377 Stomach cancer : a descriptive study of 172 cases Kawthar Messoudi Poster Presentation Basic Gastric Cancer Clinical P-378 Clinico-epidemiological profile of colorectal cancer in Algerian
patients age 40 and under : Alarming increase in incidence. SOUAD BEKOUACI Poster Presentation Clinical Colon Cancer Screening/preventio
n/epidemiology P-379 Are hepatic metastases of colorectal cancer more chemosensitive
than other metastatic sites ? SOUAD BEKOUACI Poster Presentation Clinical Colon Cancer Metastatic Disease
P-380 Skin toxicity of cetuximab in patients with metastatic colorectal
P-381 The management of neuroendocrine gastroenteropancreatic tumors. Soumia Berrad Poster Presentation Basic Other Metastatic Disease
P-382 Clinicopathologic feature of microsatellite stable early-onset
colorectal cancer Rumi Shin Poster Presentation Clinical Colon Cancer Clinical
P-383 Survival and prognostic factors for stage II colon cancer Karima Oualla Poster Presentation Clinical Colon Cancer Clinical P-384 Anal Carcinoma A comparative analysis of the standard treatment vs
An hypofractionated schedule (the Tlalpan Regime) experience at the Instituto Nacional de Cancerología, México.
Jesus Zamora Moreno Poster Presentation Clinical Other Radiation and Imaging
P-385 PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Long Pan Poster Presentation Clinical Hepatocellular Clinical
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
P-386 Interleukin-6 induced Lipocalin 2 promotes tumorigenesis from colitis to colorectal cancer
Se Lim Kim Poster Presentation Basic Colon Cancer Biomarkers
P-387 Final results of neoadjuvant Photodynamic therapy (PDT) on the indices of T - and B-cellar immune answer in the surgical treatment of patients with gastric cancer
Michail Myasnyankin Poster Presentation Clinical Gastric Cancer Biomarkers
P-388 Prospective Randomized comparison between 5-flurouracil,leucovorin and etoposide plus best supportive care with best supportive care in advanced gastric cancer
Praveen Khatri Poster Presentation Basic Gastric Cancer Metastatic Disease
P-389 Clinical Significance of BRAF Mutations in Colorectal Cancer: A Retrospective Study of One Institution in a real-life population.
Lidia Carnerero Córdoba
Poster Presentation Basic Colon Cancer Clinical
P-390 5-fluorouracil and cisplatin regulated with leucovorin for locally advanced esophageal cancer
Praveen Khatri Poster Presentation Clinical Esophageal Cancer Surgery
P-391 15-PGDH regulated PD-1/PD-L1 immune checkpoint blockade immunotherapy in colon cancer is a TNF-α dependent phenomenon.
Shakti Satapathy Poster Presentation Basic Colon Cancer Metastatic Disease
P-392 Minimally invasive surgical approach for the treatment of esophageal cancer as a component of multimodal treatment
Yestay Abzalbek Poster Presentation Clinical Esophageal Cancer Surgery
P-393 Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer: single institution experience
Nicola Personeni Poster Presentation Clinical Pancreatic Cancer Metastatic Disease
P-395 Expression of MMR in Women High Grade Carcinoma of Unknown Primary
Joni Howells Poster Presentation Clinical Other Biomarkers
P-396 PANCREATIC CANCER: Experience of Medical Oncology Department, University-Hospital Center of TIZI- OUZOU / ALGERIA
CHERIFA SEDKAOUI Poster Presentation Basic Pancreatic Cancer Clinical
P-397 BILIARY CANCERS: Experience of Medical Oncology Department, University-Hospital Center of TIZI- OUZOU/ ALGERIA.
CHERIFA SEDKAOUI Poster Presentation Basic Other Other
P-398 The use of first, second and beyond line chemotherapy for metastatic pancreatic ductal adenocarcinoma at the Royal Marsden Hospital
Oliver Butters Poster Presentation Basic Pancreatic Cancer Metastatic Disease
P-399 How does adjuvant chemotherapy for stage II colon cancer impact survival in regard of prognostic factors? A report of 147 Tunisian cases
syrine SGHAIER Poster Presentation Clinical Colon Cancer Clinical
P-400 ANCHOR CRC: A Phase 2, Open-label, Single Arm, Multicenter Study of Encorafenib (ENCO), Binimetinib (BINI), Plus Cetuximab (CETUX) in Patients With Previously Untreated BRAF V600E-mutant Metastatic Colorectal Cancer (mCRC).
Rona Yaeger Poster Presentation Basic Esophageal Cancer Biomarkers
P-401 The tumor burden rise at radiological disease progression associates with poor overall survival in advanced colorectal cancer
Eldad Taub Poster Presentation Clinical Colon Cancer Clinical
P-402 Incidence and mortality rates of cholangiocarcinoma in England Helen Morement Poster Presentation Clinical Hepatocellular PD-001 Analysis of patient screening in the phase III, international,
n/epidemiology PD-002 CCL5 is associated with poor prognosis in locally advanced
pancreatic cancer (LAPC): biomarker analysis from the randomised phase II SCALOP trial
Somnath Mukherjee Poster Discussion Clinical Pancreatic Cancer Biomarkers
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
PD-003 IDENTIFICATION OF A NANOSTRING SIGNATURE THAT DIFFERENTIATES EARLY PANCREATIC CANCERS ACCORDING TO STROMAL COMPOSITION AND PREDICTS CLINICAL OUTCOME
Francesco Sclafani Poster Discussion Basic Pancreatic Cancer Biomarkers
PD-004 Time to CA19.9 nadir: a clue for defining treatment duration of primary chemotherapy in resectable PDAC
Umberto Peretti Poster Discussion Clinical Pancreatic Cancer Clinical
PD-005 Analysis of weight loss as a prognostic factor in patients with advanced gastric cancer from the Phase 3 RAINBOW study
Wasat Mansoor Poster Discussion Clinical Gastric Cancer Metastatic Disease
PD-006 A predictive model for endoscopic ultrasonography accuracy of invasion depth in early gastric cancer
Jun Chul Park Poster Discussion Clinical Gastric Cancer Clinical
PD-007 Surgical Indication for advanced gallbladder cancer considering the optimal preoperative carbohydrate antigen 19-9 cut-off value
Yusuke Yamamoto Poster Discussion Clinical Other Clinical
PD-008 Serial circulating tumor DNA (ctDNA) monitoring to predict response to treatment in metastatic gastrointestinal cancers
Aparna Parikh Poster Discussion Clinical Other Biomarkers
PD-009 Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
Ahmed Kaseb Poster Discussion Basic Colon Cancer Biomarkers
PD-010 Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study
Andrea Casadei Gardini Poster Discussion Clinical Hepatocellular Biomarkers
PD-011 Mutational profile of non-metastatic anal squamous cell carcinoma: a restrictive high impact genetic variants analysis
Ismael Ghanem Poster Discussion Basic Other Biomarkers
PD-012 Emerging risk factors of recurrence and overall survival in a Swedish stage I-III colon cancer cohort
Erik Osterman Poster Discussion Clinical Colon Cancer Clinical
PD-013 RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC)
Yu Sunakawa Poster Discussion Clinical Colon Cancer Biomarkers
PD-014 Genome-wide association study of capecitabine-induced hand-foot-syndrome in colorectal cancer
Si-Qi Dong Poster Discussion Basic Colon Cancer Biomarkers
PD-015 Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies
Daniele Rossini Poster Discussion Clinical Colon Cancer Clinical
PD-016 Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study
Alessandra Raimondi Poster Discussion Clinical Colon Cancer Clinical
PD-017 APC I1307K and risk of colorectal neoplasia in humans and mice Stephen B Gruber Poster Discussion Basic Colon Cancer Screening/prevention/epidemiology
PD-018 Feasibility of next-generation sequencing of circulating tumor cells for predicting relapse after liver resection in metastatic colorectal cancer
KO Lam Poster Discussion Basic Colon Cancer Metastatic Disease
PD-019 Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS
Claudia Cardone Poster Discussion Clinical Colon Cancer Biomarkers
Assigned ID Abstract Title Presenting Author First Name
Presenting Author Last Name
Accepted Presentation Preference
Category Sub-category
PD-020 Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identify a heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC)
Rahul Das Poster Discussion Basic Colon Cancer Biomarkers
PD-021 Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies
Lisa Salvatore Poster Discussion Clinical Colon Cancer Metastatic Disease
PD-022 PARP-ness in Metastatic Colorectal Cancer Gianluca Mauri Poster Discussion Clinical Colon Cancer Metastatic Disease
PD-023 Survey on the Unmet Needs of Patients Living with mCRC – Learnings from an International Study
Zorana Maravic Poster Discussion Basic Colon Cancer Metastatic Disease
PD-024 Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS
Guillem Argiles Poster Discussion Clinical Colon Cancer Clinical
PD-025 Hand-foot syndrome is a biomarker of improved survival following treatment with capecitabine
Claire Palles Poster Discussion Clinical Colon Cancer Biomarkers
PD-026 Quality of life in patients treated with aflibercept and FOLFIRI for metastatic colorectal cancer: interim analysis with focus on therapy lines of the non-interventional study QoLiTrap (AIO-LQ-0113)
Ralf-Dieter Hofheinz Poster Discussion Clinical Colon Cancer Clinical
PD-027 Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis
Daniele Rossini Poster Discussion Clinical Colon Cancer Metastatic Disease
PD-028 Pattern and dynamics of metastatic sites during course of metastatic colorectal cancer (mCRC) trajectory in 1086 Finnish patients in the nationwide prospective RAXO study.
Pia Osterlund Poster Discussion Clinical Colon Cancer Metastatic Disease
PD-029 Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer
Michel Ducreux Poster Discussion Clinical Colon Cancer Clinical
PD-030 Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC)
Michael Geissler Poster Discussion Clinical Colon Cancer Metastatic Disease
PD-031 Immune signatures identify three immune clusters in mCRC, with potential clinical implications
Leire Pedrosa Poster Discussion Clinical Colon Cancer Biomarkers
PD-032 Comparison of surgical data and survival outcome of rectal cancer patients that need upfront surgery after chemoradiotherapy versus salvage surgery after watch-and-wait
Philippe Bulens Poster Discussion Clinical Rectal Cancer Clinical
PD-033 A prospective cohort study on the effect of radiotherapy for rectal cancer on female sexual function
Annika Svanström Röjvall Poster Discussion Clinical Rectal Cancer Clinical
PD-034 Clinical outcomes of rectal neuroendocrine tumors less than 20 mm: a single institutional analysis of 371 patients
Hyeong Seok Nam Poster Discussion Clinical Rectal Cancer Clinical
